Interestingly, the use of IFN-β with tamoxifen and retinoic acid showed better response rates in comparison to IFN-α in the same combination, suggesting that IFN-β might be a better anti-cancer agent than IFN-α in some clinical settings for breast cancer patients (43). Here, IFNB1 is linked to breast cancer.